免疫性血小板减少症的“按需”罗米司亭治疗
'On-demand' romiplostim therapy in immune thrombocytopenia.
作者信息
Mitrovic M, Elezovic I, Suvajdzic-Vukovic N
机构信息
Clinic of Haematology, Clinical Centre of Serbia, Belgrade, Serbia.
Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
出版信息
J Clin Pharm Ther. 2016 Jun;41(3):351-353. doi: 10.1111/jcpt.12359. Epub 2016 Feb 6.
WHAT IS KNOWN AND OBJECTIVE
Although thrombopoietin receptor agonists are a second-line treatment for refractory immune thrombocytopenia (ITP), we lack guidelines recommending maintenance modality in patients who achieve complete remission (CR).
CASE SUMMARY
We report a patient with refractory ITP who achieved CR on romiplostim. Obtaining romiplostim for 6 months of therapy, we decided to try extending this by modifying the standard treatment regimen. Romiplostim was successfully administered 'on-demand', only if the patient's platelet count dropped below 150 × 10 /L, over a period of 12 months.
WHAT IS NEW AND CONCLUSION
The strategy of 'on-demand' therapy is a promising procedure for the maintenance of response, lowering costs and improving treatment safety.
已知信息与目的
尽管血小板生成素受体激动剂是难治性免疫性血小板减少症（ITP）的二线治疗药物，但对于达到完全缓解（CR）的患者，我们缺乏推荐维持治疗方式的指南。
病例摘要
我们报告一例难治性ITP患者，使用罗米司亭后达到CR。在获得罗米司亭进行6个月治疗后，我们决定尝试通过修改标准治疗方案来延长治疗时间。在12个月的时间里，仅当患者血小板计数降至低于150×10⁹/L时，才成功“按需”给予罗米司亭。
新内容与结论
“按需”治疗策略是维持缓解、降低成本和提高治疗安全性的一种有前景的方法。
Zotero 插件